about
Digestive physiology of the pig symposium: gut chemosensing and the regulation of nutrient absorption and energy supplyA categorical structure-activity relationship analysis of GPR119 ligands.High-throughput screening for GPR119 modulators identifies a novel compound with anti-diabetic efficacy in db/db miceAngelica dahurica Extracts Improve Glucose Tolerance through the Activation of GPR119Evaluation of drug interactions of GSK1292263 (a GPR119 agonist) with statins: from in vitro data to clinical study design.A GPR119 Signaling System in the Murine Eye Regulates Intraocular Pressure in a Sex-Dependent MannerHD047703, a New Promising Anti-Diabetic Drug Candidate: In Vivo Preclinical Studies.Stimulating β-cell regeneration by combining a GPR119 agonist with a DPP-IV inhibitor.GPR40 (FFAR1) - Combined Gs and Gq signaling in vitro is associated with robust incretin secretagogue action ex vivo and in vivoDiscovery and characterization of novel small molecule agonists of G protein-coupled receptor 119.Diabetes mellitus: new challenges and innovative therapies.Targeting GPR120 and other fatty acid-sensing GPCRs ameliorates insulin resistance and inflammatory diseases.Free fatty acid receptors: emerging targets for treatment of diabetes and its complications.Lipid derivatives activate GPR119 and trigger GLP-1 secretion in primary murine L-cells.Stimulation of proglucagon gene expression by human GPR119 in enteroendocrine L-cell line GLUTag.Structure-activity relationships of fatty acid amide ligands in activating and desensitizing G protein-coupled receptor 119.In vivo efficacy of HD0471953: a novel GPR119 agonist for the treatment of type 2 diabetes mellitus.Bowels control brain: gut hormones and obesity.Diabetes area participation analysis: a review of companies and targets described in the 2008 - 2010 patent literature.Dietary fat sensing via fatty acid oxidation in enterocytes: possible role in the control of eating.Molecular physiology of glucagon-like peptide-1 insulin secretagogue action in pancreatic β cells.Discontinued drugs in 2012: endocrine and metabolic.GPR119 agonists 2009-2011.Oxadiazoles as privileged motifs for promising anticancer leads: recent advances and future prospects.Gastrointestinal hormonal responses on GPR119 activation in lean and diseased rodent models of type 2 diabetes.Biological characteristics and agonists of GPR120 (FFAR4) receptor: the present status of research.G protein-coupled receptors: signalling and regulation by lipid agonists for improved glucose homoeostasis.YH18421, a novel GPR119 agonist exerts sustained glucose lowering and weight loss in diabetic mouse model.Metal-free hydroarylation of the side chain carbon-carbon double bond of 5-(2-arylethenyl)-3-aryl-1,2,4-oxadiazoles in triflic acid.Synthesis and biological evaluation of novel 4-(2-fluorophenoxy)-2-(1H-tetrazol-1-yl)pyridines bearing semicarbazone moieties as potent antitumor agents.Structural basis for constitutive activity and agonist-induced activation of the enteroendocrine fat sensor GPR119.Agonists at GPR119 mediate secretion of GLP-1 from mouse enteroendocrine cells through glucose-independent pathways.Glucose-lowering effects and safety of DS-8500a, a G protein-coupled receptor 119 agonist, in Japanese patients with type 2 diabetes: results of a randomized, double-blind, placebo-controlled, parallel-group, multicenter, phase II study.Pharmacological inhibition to examine the role of DGAT1 in dietary lipid absorption in rodents and humans.A facile approach to synthesize 3,5-disubstituted-1,2,4-oxadiazoles via copper-catalyzed-cascade annulation of amidines and methylarenes.Effects of JNJ-38431055, a novel GPR119 receptor agonist, in randomized, double-blind, placebo-controlled studies in subjects with type 2 diabetes.Synthesis and biological evaluation of 1, 2, 4-oxadiazole derivatives as novel GPR119 agonists.YH18968, a Novel 1,2,4-Triazolone G-Protein Coupled Receptor 119 Agonist for the Treatment of Type 2 Diabetes Mellitus.Discovery of 5-methyl-2-(4-((4-(methylsulfonyl)benzyl)oxy)phenyl)-4-(piperazin-1-yl)pyrimidine derivatives as novel GRP119 agonists for the treatment of diabetes and obesity.
P2860
Q27027642-FDAA2F68-17CF-497F-9BD2-3AFF2DE08C85Q27311495-B6324E2A-0578-484F-B2EA-6E14B0A775C7Q28533161-2269D7DF-C84D-4015-9A87-FF6D28DA0614Q28552543-16EEB942-2C9C-4CD7-BA56-319B755869A8Q30582571-DC0DDF7E-E010-4415-9C58-C1C1B49947D4Q33792933-03F8367E-C364-4FB5-9B12-85B02AA39466Q34360545-B0D13500-3F7E-49FA-9E94-8D4F1F700909Q34575201-03F42A34-2EEF-4D2A-A737-89135C9282A9Q35040481-406F70E2-E18A-423E-B0BC-9E1E30DB8DCEQ35135054-FB01BAB7-662D-4670-87F8-D657AF315CF6Q36117595-EBC9C464-92E6-40FF-A244-05E2C44649B8Q36165684-E4840BC8-F81F-431F-AC2D-42C576C357B3Q36327956-EDC48808-88C7-4DA5-ABF1-8FFBAE132FEBQ36677839-AEF26138-E516-4D88-BED8-370EDFE9057BQ37050355-9CF05159-732D-45A9-A662-57A227C6ADDDQ37379380-B90E5EDC-25FF-49EF-B23A-9A75F4702E9DQ37412882-546C204D-4E02-4481-ADC9-AD03280A0F65Q37508420-EE9131C3-3053-4BC7-900F-771B336EA3D0Q37810292-2F3BC28B-5876-4861-85EA-EEDA17E9AF83Q37819529-2127003F-4982-4C35-8D53-67E45F728E56Q37904176-9F3936E2-E3BD-450A-832C-9730BA1520A8Q38130293-F3320598-284D-4419-96A1-DFC0DD6849A8Q38162927-44F47099-64F7-441C-A57C-4644566BF624Q38165135-3EA1E902-3D7D-4848-B1BC-3B94D51DF9C3Q38309551-38C39FC4-F8B8-4A38-9F66-73F4B0364729Q38558377-3906C9C8-4A67-4A69-A337-67D7FF370DAEQ38688833-9B4C5F4E-80DA-4C63-978D-E16534121E2DQ38737053-7B68F159-D35B-4C3B-80D3-12E637BBC7E9Q38762666-A7AD631D-5448-45A8-8891-C7B241E3C634Q39082051-CA5DB80B-A943-4416-A5A5-1F65972C612AQ39145769-DBF44E46-A941-458E-BB18-AE25B4C002DFQ39452270-8724C2D6-AD8F-4626-9B05-ABBF2D0913A2Q42699213-CDD7607F-D34F-4C22-850E-673059855765Q46680329-689DF135-CEA4-4287-8294-1FED81591D33Q50278841-D6673CE2-86EF-48C4-9ECB-0DE77AFEBF38Q51359689-639DA8CB-C677-43BD-A335-7149BC83CC46Q51364075-9427F922-1644-4C04-97E4-C9E905D864D0Q52679204-A10CD766-F3E1-441A-BA3A-DB581FEFFA2BQ53192248-47BE7515-7B1C-407E-AFB5-9FEFADFE9CA4
P2860
description
2009 nî lūn-bûn
@nan
2009 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
GPR119 agonists for the treatment of type 2 diabetes
@ast
GPR119 agonists for the treatment of type 2 diabetes
@en
GPR119 agonists for the treatment of type 2 diabetes
@nl
type
label
GPR119 agonists for the treatment of type 2 diabetes
@ast
GPR119 agonists for the treatment of type 2 diabetes
@en
GPR119 agonists for the treatment of type 2 diabetes
@nl
prefLabel
GPR119 agonists for the treatment of type 2 diabetes
@ast
GPR119 agonists for the treatment of type 2 diabetes
@en
GPR119 agonists for the treatment of type 2 diabetes
@nl
P2093
P2860
P3181
P1476
GPR119 agonists for the treatment of type 2 diabetes
@en
P2093
Daniel J Buzard
James N Leonard
Juerg Lehmann
Robert M Jones
P2860
P304
P3181
P356
10.1517/13543770903153878
P407
P577
2009-10-01T00:00:00Z